Novartis Gets FDA Approval for Lutathera in Pediatric Treatment
By Dean Seal
Novartis said federal regulators have approved its Lutathera therapy as a treatment for pediatric patients with certain gastroenteropancreatic neuroendocrine tumors.
The Swiss pharmaceutical company said Tuesday that the Food and Drug Administration has approved the therapy for the treatment of patients aged 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, including foregut, midgut, and hindgut neuroendocrine tumors.
The approval makes Lutathera the first therapy that has been specifically reviewed and approved for use in pediatric patients with gastroenteropancreatic neuroendocrine tumors, Novartis said.
The approval was based on a trial that reported a safety profile for Lutathera that was consistent with an adult population in a previous study that ultimately got the therapy approved for adult patients.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
April 23, 2024 14:18 ET (18:18 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations